3489 Canterbury Place
57 articles with biOasis
Bioasis Technologies Inc. announced that it has granted stock options to acquire a total of 1,576,240 common shares at a price of $0.27 per share to directors and officers of the company, including 510,000 options granted to Mario Saltarelli, who joined the board as a new director in May 2019 and 391,240 options granted to Deborah Rathjen, President & Chief Executive Officer, in lieu of cash compensation.
Bioasis Announces Allowances of Patent Applications in the U.S. and Europe Relating to xB3 Platform Technology and Key Therapeutic Indications
U.S. Patent Office and European Patent Office issue allowances of patent applications relating to iduronate-2-sulfatase (“IDS”) polypeptide/xB3 conjugates
BIOASIS TECHNOLOGIES INC. announced that it has applied for approval from the TSX Venture Exchange to extend the expiry date of 5,797,795 common share purchase warrants issued to subscribers pursuant to the private placement of units which closed on April 11, 2017.
BIOASIS TECHNOLOGIES INC. today announced that its board of directors has appointed Dr. Deborah A. Rathjen as president and chief executive officer.
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2018
BIOASIS TECHNOLOGIES INC. announced that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended Nov. 30, 2018.
1/18/2019Pharma and biotech companies make changes to their board and leadership teams to advance pipelines and strategies, at SQZ, AstraZeneca, Bioasis, and more.
1/11/2019Biopharma companies strengthen the leadership teams during the annual J.P. Morgan Healthcare Conference.
Bioasis Announces Agreement With Leading Pharmaceutical Company for Pre-Clinical Research Using the xB3 Platform Technology
Under the terms of the Material Transfer Agreement, Bioasis will receive $500,000
12/17/2018With the year closing out, biotech and pharma companies are making adjustments to their leadership ranks and boards of directors.
Under the terms of the agreement, Bioasis to receive a US$1 million upfront payment from Prothena, plus additional potential option exercise, regulatory and commercial milestone payments, plus additional royalties on net sales from licensed products
Inc. magazine collates an annual list of the fastest-growing private companies in America. This year, 15 of the top 5,000 were related to healthcare, medical devices and biopharma.
8/13/2018GSK's Hal Barron, former Juno Chief Executive Officer and others take on or transition into new roles. Let's take a look at some of those!
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2018
BIOASIS TECHNOLOGIES INC. announced that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended May 31, 2018.
BIOASIS TECHNOLOGIES INC., a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier for the treatment of central nervous system disorders, today announced the appointments of John E. Curran, CPA and David M. Wurzer, CPA to the Bioasis Board of Directors, filling two of the current vacancies on the board.
Bioasis Announces Positive Results from a Microdialysis Study Showing Lead Investigational Candidate xB3 ™-001 Increased Brain Activity
The Company has filed a patent application based on these observations and those data may have broader applicability
Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic
Bioasis and BioAgilytix today announced a strategic collaboration to partner on the development and validation of bioanalytical methods to support and advance the xB3 TM-001 program.
Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’Connor
BIOASIS TECHNOLOGIES INC. today announced the addition of Mario Saltarelli, M.D., Ph.D., Jack Hoppin, Ph.D. and Sue O’Connor, B.Sc. (Hons), Ph.D. to its scientific advisory board.
Research Conducted by MedImmune Shows the xB3 Platform Efficiently Delivers Antibodies Across the BBB at Therapeutic Doses xB3 Demonstrated Sustained Systemic PK Properties of the MedImmune Antibody Constructs and Demonstrated a Strong PK/PD Dose Dependent Relationship in a Neuropathic Pain Pre-Clinical Model
Bioasis and WuXi Biologics Announce Initial Strategic Collaboration for the Development and Manufacturing of xB3-001, the Company’s Lead Investigational Candidate to Treat Brain Cancer
Bioasis will draw on WuXi Biologics’ expertise in developing complex biologic molecules for production of xB3-001 to support analytical development, formulation and IND-enabling in vivo studies
BIOASIS TECHNOLOGIES INC announce today a private placement of units (the "Units") at a price of C$0.552 per Unit